Form **8937**(December 2017) Department of the Treasury Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-0123

Part	Reporting	Issuer			•			
1 lss	suer's name				2 Issuer's employer identification number (EIN)			
E	T				44,0700474			
	Therapeutics, Inc. ame of contact for add	ditional information	46-3733671 5 Email address of contact					
3 IVa	arrie or corriact for aut	uitionai information	5 Email address of contact					
Invest	or Relations			415-887-1471	info@eidostx.com			
6 Nu	umber and street (or F	P.O. box if mail is not	7 City, town, or post office, state, and ZIP code of contact					
	ontgomery St. Ste 20 ate of action	000	San Francisco, California 94104					
0 00	ite of action		3 Olass	sification and description				
Janua	ry 26, 2021		Commor	Stock				
	JSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)			
	28249H104			EIDX				
Part					See back of form for additional questions.			
			applicable, the	e date of the action or the d	late against which shareholders' ownership is measured for			
ι	the action ► See Att	ached						
15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per								
\$	share or as a percenta	age of old basis \triangleright S	ee Attached					
	Describe the calculation dates See		pasis and the	data that supports the calc	ulation, such as the market values of securities and the			

Pai	rt II		Organizational Action (continued)			
17			applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatn	nent i	s based ▶	See Attached
18	Can	n any	resulting loss be recognized? ► See Attached			
10	Dua	المائد .			. .	to also al
19	Prov	vide a	any other information necessary to implement the adjustment, such as the reportable tax	x yea	See At	tached
	ι	Jnder	penalties of perjury, I declare that I have examined this return, including accompanying schedules	and s	statements,	and to the best of my knowledge and
	b	oelief,	it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information	on of v	vhich prepar	er has any knowledge.
Sign						
Her	e s	Signat	ture Date	e► _	2/17/2021	
		Dut :	Cameron Turtle		Chief Busine	ess Officer
			vour name ► Cameron Lurtle Print/Type preparer's name Preparer's signature Da			- PTIN
Pai			· · · · · · · · · · · · · · · · · · ·			Check if if P00439876
Pre		C.	Firm's name ► BDO USA, LLP			Firm's EIN ► 13-5381590
Use	or Ur	шу	Firm's address 200 Ottawa Ave NW Ste 300, Grand Rapids, MI 49503			Phone no. 616-774-7000
Send	l Forr		37 (including accompanying statements) to: Department of the Treasury, Internal Revenu	ue Se		

Eidos Therapeutics, Inc.

FEIN: 46-3733671

Attachment for Form 8937

Part II

Line 14

On January 26, 2021, BridgeBio Pharma, Inc. ("BridgeBio") completed the acquisition of Eidos Therapeutics, Inc. ("Eidos") by way of two mergers with indirect wholly owned subsidiaries of BridgeBio as follows: (i) on January 26, 2021, Globe Merger Sub I, Inc. ("Merger Sub I") merged with and into Eidos (the "First Merger") with Eidos continuing as the surviving corporation, and (ii) immediately after the First Merger on January 26, 2021 and as a part of the same plan, Eidos merged with and into Globe Merger Sub II, Inc. ("Merger Sub II"), a wholly owned indirect subsidiary of BridgeBio, with Merger Sub II continuing as the surviving corporation (the "Second Merger" and together with the First Merger, the "Mergers"). Pursuant to the Mergers, each issued and outstanding share of Eidos common stock (including restricted stock, each an "Eidos Share" and together the "Eidos Shares"), other than the issued and outstanding Eidos Shares owned by BridgeBio prior to the Mergers which represented approximately 63.7% of the Eidos Shares, was exchanged, at each former Eidos shareholder's election, for either (a) 1.85 shares of BridgeBio common stock (each a, "BridgeBio Share" and together the "BridgeBio Shares") and cash in lieu of any fractional shares, or (b) \$73.26 as cash consideration. Each of Eidos stock options issued and outstanding as of the Mergers yields 1.8511 BridgeBio Shares upon exercise. The information set forth in this attachment is relevant to former Eidos shareholders who received BridgeBio Shares in the Mergers.

Additional details regarding the Mergers and the U.S. federal income tax consequences of the Mergers can be found in the definitive proxy statement filed with the SEC on December 15, 2020 (File No. 333-24994) and available at the following link:

https://www.sec.gov/Archives/edgar/data/1743881/000119312520317638/d87012ddefm14a.htm

<u>Line 15</u>

BridgeBio and Eidos intend, for U.S. federal income tax purposes, that the Mergers, taken together, will qualify as a "reorganization" within the meaning of Section 368(a) of the Internal Revenue Code of 1986 and the remainder of this attachment assumes such treatment. Accordingly, the aggregate tax basis in the BridgeBio Shares received in the Mergers, including any fractional share interest deemed received and exchanged for cash, will generally equal the former Eidos shareholder's aggregate tax basis in the Eidos Shares surrendered in the Mergers.

If former Eidos shareholders acquired different blocks of Eidos Shares at different times or at different prices, such shareholders' basis and holding period in their BridgeBio Shares received in the Mergers may be determined with reference to each block of Eidos Shares.

Any cash received in lieu of a fractional BridgeBio Share will be treated as a sale of that fractional share.

Line 16

See the discussion in Line 15 above.

Line 17

Section 368(a)(2)(D)

Section 354(a)

Sections 358(a) and (b)

Section 302

Line 18

In general, former Eidos shareholders will not recognize loss for U.S. federal income tax purposes on the receipt of BridgeBio Shares in the Mergers, except with respect to the cash received in lieu of fractional BridgeBio Shares as described in Line 15 and Line 16 above.

Line 19

The merger and resulting stock exchange were effective January 26, 2021. Therefore, the reportable tax year is the 2021 calendar year.